强生公司50亿美元阿尔茨海默病希望破灭,抗tau抗体posdinemab二期试验失败
J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2
生物技术与制药领域的最新动态
J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2
Abbott to replace certain FreeStyle Libre 3 CGMs after incorrect readings and death reports
Gilead hatches $400M biobucks deal for Swedish biotech’s TREX1 cancer program
Novo shares tumble after 2 trial misses for semaglutide in Alzheimer's disease
'People are getting used to it': Global uncertainties can't dampen upbeat Jefferies conference
Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone
Solventum to buy Acera Surgical for up to $850M, repurchase $1B in stock
J&J MedTech bolsters stroke R&D programs in Ireland
How COVAX raced to protect the world from COVID-19
The apple of my eye: How I’ve created a plant-health tracker for farmers in Tanzania
Beyond growth — why we need to agree on an alternative to GDP now
Introducing the j-metric: a true measure of what matters in academia
Fall-prevention clinical trial in rural China shows promising results
Daily briefing: This enigmatic figure reveals a common ancient myth
AI has a democracy problem — here’s why
Measles makes a comeback: four charts show where and how
Honouring visionary scientist and Nature’s founder, Norman Lockyer
Fishing around offshore wind farms could boost both conservation and green energy
Google DeepMind won a Nobel prize for AI: can it produce the next big breakthrough?